Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue Infections
Open Access
- 15 November 2003
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 37 (10) , 1298-1303
- https://doi.org/10.1086/379015
Abstract
Dalbavancin, a novel glycopeptide with a long elimination half-life (∼9–12 days), was compared to standard antimicrobial therapy for skin and soft-tiKeywords
This publication has 8 references indexed in Scilit:
- In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and CorynebacteriaAntimicrobial Agents and Chemotherapy, 2003
- Once‐Daily, High‐Dose Levofloxacin versus Ticarcillin‐Clavulanate Alone or Followed by Amoxicillin‐Clavulanate for Complicated Skin and Skin‐Structure Infections: A Randomized, Open‐Label TrialClinical Infectious Diseases, 2002
- Linezolid versus Vancomycin for the Treatment of Methicillin‐ResistantStaphylococcus aureusInfectionsClinical Infectious Diseases, 2002
- Once‐Daily Intravenous Cefazolin Plus Oral Probenecid Is Equivalent to Once‐Daily Intravenous Ceftriaxone Plus Oral Placebo for the Treatment of Moderate‐to‐Severe Cellulitis in AdultsClinical Infectious Diseases, 2002
- Ertapenem Once Daily Versus Piperacillin‐Tazobactam 4 Times per Day for Treatment of Complicated Skin and Skin‐Structure Infections in Adults: Results of a Prospective, Randomized, Double‐Blind Multicenter StudyClinical Infectious Diseases, 2002
- In VitroEvaluation of BI 397, a Novel Glycopeptide Antimicrobial AgentJournal of Chemotherapy, 2001
- Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycinJournal of Antimicrobial Chemotherapy, 1999
- In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibioticJournal of Antimicrobial Chemotherapy, 1999